Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/22936
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMilionis, H. J.en
dc.contributor.authorPapakostas, J.en
dc.contributor.authorKakafika, A.en
dc.contributor.authorChasiotis, G.en
dc.contributor.authorSeferiadis, K.en
dc.contributor.authorElisaf, M. S.en
dc.date.accessioned2015-11-24T19:28:56Z-
dc.date.available2015-11-24T19:28:56Z-
dc.identifier.issn0091-2700-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/22936-
dc.rightsDefault Licence-
dc.subjectAnalysis of Varianceen
dc.subjectBlood Glucose/drug effectsen
dc.subjectFemaleen
dc.subjectFenofibrate/pharmacology/*therapeutic useen
dc.subjectHeptanoic Acids/pharmacology/*therapeutic useen
dc.subjectHomocysteine/*blooden
dc.subjectHumansen
dc.subjectHyperlipidemias/diet therapy/*drug therapy/metabolismen
dc.subjectHypolipidemic Agents/pharmacology/*therapeutic useen
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subjectPyrroles/pharmacology/*therapeutic useen
dc.subjectSimvastatin/pharmacology/*therapeutic useen
dc.subjectUric Acid/blooden
dc.titleComparative effects of atorvastatin, simvastatin, and fenofibrate on serum homocysteine levels in patients with primary hyperlipidemiaen
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/12953339-
heal.identifier.secondaryhttp://jcp.sagepub.com/content/43/8/825.full.pdf-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate2003-
heal.abstractHyperhomocysteinemia is regarded as an independent risk factor for cardiovascular disease. Lipid-lowering agents, such as fibrates, can modify homocysteine levels. However, less is known about the effect of statin therapy on homocysteine. The authors compared the effects of atorvastatin (40 mg/day), simvastatin (40 mg/day), and micronized fenofibrate (200 mg/day) on the serum concentrations of total homocysteine, vitamin B12, and folic acid in patients with primary hyperlipidemia. A total of 128 patients with primary hyperlipidemia (total cholesterol > 240 mg/dL and triglycerides < 350 mg/dL) were assigned to atorvastatin, simvastatin, or fenofibrate. Serum lipid and metabolic parameters were measured at baseline and at 6 and 12 weeks of treatment. Homocysteine correlated positively with serum creatinine and uric acid levels and inversely with serum folic acid levels. All treatment modalities reduced total, low-density lipoprotein (LDL) cholesterol, and triglyceride concentrations. High-density lipoprotein (HDL) cholesterol levels significantly increased only in the fenofibrate-treated patients (47.9 +/- 12.5 vs. 50.7 +/- 12.6 vs. 51.2 +/- 12.8 mg/dL, p < 0.01). Atorvastatin and fenofibrate treatment resulted in a significant reduction of serum uric acid levels (5.3 +/- 1.6 vs. 4.9 +/- 1.4 vs. 4.8 +/- 1.4 mg/dL, p < 0.0001 for atorvastatin; 5.6 +/- 1.6 vs. 4.3 +/- 1.4 vs. 4.4 +/- 1.4 mg/dL, p < 0.0001 for fenofibrate). Homocysteine levels were significantly increased only by fenofibrate (10.3 +/- 3.3 vs. 14.1 +/- 3.8 vs. 14.2 +/- 3.6 microU/L, p < 0.001) but did not change from baseline following statin treatment. Neither statins nor fenofibrate had any effect on serum vitamin B12 and folic acid levels. In contrast to fenofibrate, therapeutic dosages of atorvastatin and simvastatin have a neutral effect on serum homocysteine levels, which is in favor of their "cardioprotective" properties.en
heal.journalNameJ Clin Pharmacolen
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ

Files in This Item:
File Description SizeFormat 
Milionis-2003-Comparative effects.pdf152.18 kBAdobe PDFView/Open    Request a copy


This item is licensed under a Creative Commons License Creative Commons